Trial Profile
Mepolizumab for the Treatment of Eosinophilic Fasciitis; An Open-Label, Single-Arm, Exploration Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Eosinophilic fasciitis
- Focus Proof of concept; Therapeutic Use
- 13 Feb 2023 Planned End Date changed from 15 Dec 2025 to 1 Dec 2025.
- 13 Feb 2023 Planned primary completion date changed from 15 Dec 2025 to 1 Dec 2025.
- 13 Feb 2023 Planned initiation date changed from 1 Jan 2023 to 1 Mar 2023.